

Ergotism- a Forgotten Enemy

Corresponding Author*

Dr. S. Bharani, MBBS., DNB (Anaesthesia)

Department of Anaesthesiology,

Dr. Jeyasekharan Hospital & Nursing home, Nagercoil.

Author 1: Dr. Nithya Priyadharshini DA, DNB, Consultant, Dr. Jeyasekharan Hospital & Nursing home, Nagercoil.

Author 2: Dr. Renu Devaprasath MBBS, DA, DNB, Head of Department, Dr. Jeyasekharan Hospital & Nursing home, Nagercoil.

Author 3: Dr. Anand Karthik DA, Senior consultant, Dr. Jeyasekharan Hospital & Nursing home, Nagercoil.

doi: 10.51505/ijmshr.2026.10114

URL: <http://dx.doi.org/10.51505/ijmshr.2026.10114>

Received: Jan 01, 2026

Accepted: Jan 15, 2026

Online Published: Feb 17, 2026

Abstract

Background:

Ergot alkaloid medications are used for the treatment of migraine, vascular headache, control of PPH. Ergotism is an uncommon but serious condition caused by intense peripheral vasospasm following ergot alkaloid use. Although its incidence has declined, it may still present in patients using ergotamine-containing medications for migraine. Early recognition is crucial to prevent irreversible ischemic injury. Our case emphasizes the potential for complete reversibility of vascular changes if recognized early. This case highlights the importance of considering ergotism in patients with unexplained ischemia and a history of ergotamine use. Prompt diagnosis, discontinuation of the ergot and other vasoconstrictors, initiation of vasodilator therapy with sodium nitroprusside and timely consideration of endovascular intervention can prevent irreversible ischemia.

Keywords: Ergotism; Ergotamine; Acute limb ischemia; Vasospasm; Sodium nitroprusside.

Introduction

Atherosclerosis is present in the great majority of people with peripheral arterial disease. A small percentage of cases are caused by inflammatory artery illnesses, thrombotic disorders, or thromboembolism. With an incidence rate of 0.001 to 0.002%, ergotism in patients taking ergotamine formulations for recurring headaches is even less common. [1] Ergotism or “Saint Anthony’s fire” is a rare but potentially devastating complication of ergot alkaloid therapy for migraine, characterized by intense vasospasm that may precipitate peripheral ischemia and gangrene [2,3]. Although uncommon, this condition should be considered in cases of acute limb

ischemia where common risk factors (like atherosclerosis) are absent but there is history of ergotamine use [2,4]. Early recognition and prompt intervention are critical to prevent irreversible outcomes.

The first-line management for suspected ergotism involves immediate discontinuation of the offending agent and initiation of vasodilatory therapy. Sodium nitroprusside, a potent direct arterial vasodilator, has been successfully used via continuous intra-arterial or intravenous infusion to reverse ergotamine-induced vasospasm and restore peripheral perfusion in several documented cases [3,5].

In this case report, we describe a 45-year-old woman who experienced acute bilateral lower-limb ischemia after short-term use of ergotamine–caffeine medication. With rapid diagnosis and administration of intravenous sodium nitroprusside, we achieved full restoration of pulses, underscoring the importance of timely therapeutic action in ergot-induced peripheral ischemia.

Informed Consent:

Informed consent was obtained from the patient for the purpose of publication.

Clinical case

A 45-year-old woman presented with a one-day history of severe burning pain and cramps in her left leg. Treatment at another hospital included intramuscular tramadol and IV calcium gluconate for the same. Following this, she acutely developed hypotension, which was managed with intravenous fluids and a noradrenaline infusion. She was then referred to our facility for further care.

On arrival, patient was conscious and responsive, still complaining of intense left leg pain. Her vital signs were: HR 110 /min, BP 150/90 mm Hg on noradrenaline at 2.6 µg/min, RR 20/min (regular, non-acidotic), and SpO₂ 98% on 2 L/min oxygen. There was no fever, pallor, jaundice, pedal oedema, or lymphadenopathy. All peripheral extremities appeared cold, clammy, and dusky, with the lower limbs more affected than the upper. Bedside Doppler showed biphasic flow in all the peripherals.

Table 1: Pulse

Pulse Site	Present / Palpable?	Volume / Quality
Carotids	Present	Good
Brachial	Palpable	Good
Femoral	Palpable	Good
Radial	Palpable	Feeble
Ulnar	Palpable	Feeble
Popliteal	Palpable	Good
Dorsalis Pedis (foot)	Not Palpable	— (Absent)
Posterior Tibial (ankle)	Not Palpable	— (Absent)




Figure: Pulse sites

Past Surgical & Medication History

Ten days prior, she had undergone a laparoscopic right nephrectomy for a nonfunctional kidney; the perioperative period was uneventful, and she was discharged on postoperative day 4. Medications on admission included Tab. Thyronorm 50 µg once daily, Amlodipine 2.5 mg twice daily, Tab. Clonazepam 0.5 mg once daily at night.

Diagnostic Workup & Initial Management

Vascular surgeon opinion was obtained, and a therapeutic heparin infusion was initiated (500 units/mL at 2 mL/h). Laboratory results showed a marked leukocytosis (31,000 cells/mm³) and elevated lactate (4.1 mmol/L); all other parameters were within normal limits. A CT angiogram revealed occlusion of arterial blood flow distal to the bilateral superficial femoral artery (SFA) junction.



Figure 2: CT Angiogram shows occlusion of arterial blood flow distal to the bilateral superficial femoral artery (SFA) junction.

With this diagnosis of ongoing critical limb ischemia, the patient underwent an emergency left lower-limb endovascular procedure under general anaesthesia (due to ongoing anticoagulation-Heparinisation). Procedurally, it was uneventful; postoperative assessment showed restored peripheral pulses in the left lower limb, though other limbs remained cold and clammy. Further evaluation on postoperative day 1, the patient reported the history of occasional headaches self-managed herself with an over-the-counter medication taken off-label. A detailed history revealed chronic migraine managed with intermittent ergotamine-caffeine tablets (Migrall EC: ergotamine

1 mg + caffeine 100 mg), taken for 4–5 days after discharge. This finding raised a strong suspicion for ergotism vasospastic ischemia induced by ergotamine. We promptly discontinued ergotamine and initiated an intravenous infusion of sodium nitroprusside, an arterial vasodilator. The infusion began at 0.4 µg/kg/min and was titrated up to 2 µg/kg/min, with careful monitoring of vitals, peripheral pulses, and limb warmth every 15 minutes. Within approximately 10 hours, peripheral pulses returned across all limbs and limb warmth gradually improved. Her vitals were stable throughout and the nitroprusside infusion was discontinued gradually after 10 hours.

Discussion

Ergot, the sclerotia of *Claviceps purpurea* producing ergot alkaloids, can cause ergotism when ingested through contaminated grains such as rye or via medications containing ergotamine [6,7]. Historically, ergot derivatives have been used to manage vascular headaches, migraines, postpartum hemorrhage, and to hasten labor since the 1500s [8,9]. The primary pharmacological effect of ergot alkaloids is potent vasoconstriction via α -adrenergic receptor stimulation on vascular smooth muscle, which can be exacerbated by endothelial injury, catecholamines, and other vasoactive substances, potentially leading to thrombosis, ischemia, or vessel wall fibrosis [10–13]. Rectal administration, particularly of ergotamine caffeine suppositories, results in more efficient absorption than oral intake, with the liver as the primary site of metabolism. Although ergot-induced vasospasm can affect any vascular bed, it most commonly involves the lower limbs, occasionally resulting in acute limb ischemia or gangrene [3,4].

In our patient, sudden burning pain, dusky extremities, elevated lactate, and CT angiography findings in the context of recent ergotamine–caffeine (Migrall EC) use confirmed the diagnosis of ergotism. Immediate cessation of the offending agent is essential, and in severe ischemia, pharmacologic vasodilation is required. Sodium nitroprusside, administered intravenously and titrated from 0.4 to 2 µg/kg/min under careful monitoring, restored peripheral perfusion within 10 hours [3,14]. Alternative agents, including calcium channel blockers, tolazoline, and prostaglandin E1, have variable efficacy, while refractory cases may necessitate surgical interventions such as sympathectomy or angioplasty [4,15]. Delayed diagnosis or inadequate therapy has been associated with irreversible tissue loss and amputation, emphasizing the importance of early recognition and intervention [15].

This case highlights three critical points: (i) clinicians should maintain a high index of suspicion for ergotism in unexplained acute limb ischemia, especially with a history of ergot use; (ii) prompt initiation of sodium nitroprusside infusion can prevent irreversible ischemic injury; and (iii) vigilant, multidisciplinary management with frequent reassessment is essential to optimize outcomes.

Conclusion

Ergotism remains a rare but serious cause of acute limb ischemia, often overlooked in the modern era due to the reduced use of ergot alkaloids. However, as this case illustrates, patients may still present with life-threatening vasospasm following ergotamine intake. Early recognition of the condition, prompt withdrawal of the offending agent, and initiation of targeted vasodilator therapy are critical to preventing irreversible ischemic damage.

Sodium nitroprusside infusion has proven to be a safe and effective therapeutic option for reversing ergotamine-induced vasospasm and restoring peripheral perfusion.

Multidisciplinary management, vigilant hemodynamic monitoring, and timely intervention remain the cornerstones of successful outcomes. This case highlights the need for clinicians to maintain a high index of suspicion for ergotism in atypical presentations of acute ischemia and reinforces the therapeutic value of sodium nitroprusside in such scenarios.

Informed consent

Journal of Anaesthesia and Critical Care Case Reports (eISSN: 2454-7174)
PATIENT CONSENT FORM

I B. BUVA NBS Wani hereby give my consent and authorize the journal (both print and online edition) to use the image(s) and related information during my treatment. I understand that such imaging records and information may be published by Journal of Anaesthesia and Critical Care Case Reports and/or any party acting under the license and authority of Journal of Anaesthesia and Critical Care Case Reports, in any print, visual, electronic or broadcast media, specifically including, but not limited to, medical journals and textbooks, scientific presentations and teaching courses and Internet websites, for the purpose of informing the medical profession or the general public about surgery methods, results, issues, trends, concerns and similar matters.

I understand that I may refuse to sign this authorization and such refusal will have no effect on the medical treatment I receive.

I understand that my name and identity will not be disclosed. Once signed, I cannot revoke my consent.

I grant this consent as a voluntary contribution in the interest of public education and certify that I have read the above information and fully understand its terms.

I hereby warrant that I am over twenty-one years of age, and competent to contract in my own name.

Name of patient: B. BUVA NBS Wani

Date of Birth (DD/MM/YY): 31/3/80

Signature/thumb impression of patient (or signature/thumb impression of the person giving consent on behalf of the patient):

Relationship to the patient in case of other person signing/providing thumb impression for the consent: A. Bala Murugan

Address: 91/37₄ MOSBS St. Naza keth

Date: 30/9/25

Ethical committee approval

Dr. JEYASEKHARAN MEDICAL TRUST ETHICS COMMITTEE
Dr. JEYASEKHARAN HOSPITAL & NURSING HOME
 K.P.ROAD, NAGERCOIL 629 003, K.K.DISTRICT, TAMILNADU, INDIA
 Phone : (04652) 230019, 230020
 E-mail : jeyasekharanmedicaltrust@gmail.com Website : www.jeyasekharanmedicaltrust.com
 Registration No : EC / NEW / INST / 2023 / TN / 0231
 Head of Institution : Dr.Devaprasath Jeyasekharan. M.S. (General Surgery), F.A.M.S. (Urology), F.R.C.S. (Edin) - Ex-officio member

Chairperson
Dr.K.U.Suresh Balan, M.D. (Comm.Med.), DCH.,
 K.K.Govt. Medical College, Nagercoil.
 Res : 40/A1, Blessing, Ranithottam, Nagercoil 629 002.
 Cell: 94434 01581 surbal65@yahoo.co.in

Members :

Basic Medical Scientist :
Dr. S.J. Sushmita Ann, M.D. (Pharmacology),
 Govt. Head Quarters Hospital, Padmanabhapuram
 Res : 141, Yesudian Street, Nagercoil-629 001.
 Cell : 94861 77869 sushmitaruban@gmail.com

Clinician-Alt. Member Secretary :
Dr. Alex Francisco Nicholas, M.D.(Anaes.),
 Res : 5E, Chidambara Nathan Street, Nagercoil -1.
 Cell : 94430 54584 alexfn@gmail.com

Social Scientist :
Rev. Onacimus Sahayam
 Pastor / Theologian,
 Res : C.S.I. Parsonage, Achankulam,
 Kottaram (P.O.) - 629 703.
 Cell : 94435 95801 donsahsunil@gmail.com

Legal Expert :
Mrs.Shahila Pravin,
 Advocate,
 Res : 80, Henry Road, Nagercoil - 629 001.
 Cell : 94421 12719 shahilapraavin@gmail.com


Lay Person :
Mrs.Sabine Natarajan @ Anitha Natarajan
 Social Worker,
 Res :515/A, Pioneer Subramonian Illam,
 M.S. Road, Vetturmimadam, Nagercoil - 629 003.
 Cell : 98940 37095 shabineenataraj@gmail.com

Other Supporting Staff :

Mrs.Beena Sabu
 Administrator, Dr. JMT,
 Res : 1233, Perumal Street, K.P. Road, Nagercoil-3.
 Cell : 98421 16260 sabubeena724@yahoo.com

Dr. Ninoo George, M.D.(Int.Med),D.M.(Nephro.),
 Nephrologist, Dr. JMT,
 Res : 4/1, Paravilagam, Mulagumoodu P.O.-629167.
 Cell : 99621 07649 ninoojorge@gmail.com

Mr. Prakash George Arunachalam,
 Theologian,
 Res : 43A1/2A, Asaripallam Road, Nagercoil-629 001.
 Cell : 81304 67766 pgeorge74@gmail.com



Member Secretary
Dr.Renu Devaprasath, DNB. (Anaes.)
 Medical Administrator, Dr. JMT,
 Res : 'Swagat', 1231, Perumal Street, K.P.Road, Nagercoil-629 003,
 Cell : 98421 39630 rdevaprasath@gmail.com

Ref. No. JC/4/1496/2025 26/09/2025

Dr.Bharani.S.,
 DNB Registrar (Anaesthesiology),
 Dr.Jeyasekharan Medical Trust,
 K.P.Road, Nagercoil - 629 003.

Sub: JMT-IEC Approval for the Case Report for Publication Titled
"Ergotamine - A Forgotten Enemy".

Dear Dr.Bharani.S,


We received your application to do the publication of Case Report Titled "Ergotamine - A Forgotten Enemy" on 26/09/2025 and the following documents were reviewed at the Institutional Ethics Committee meeting.


1. Study Protocol
2. Informed Consent Document (ICD) in English
3. Informed Consent Document (ICD) in local language - Tamil

The following members of JMT - IEC were present at the meeting.

Name of the Member	Designation & Role at JMT-EC
Dr.Renu Devaprasath	Member Secretary
Dr.Sushmita Ann	Basic Medical Scientist/ <i>Acting chair person</i>
Dr.Alex Francisco Nicholas	Clinician - Alt. Member Secretary
Mrs.Shahila Pravin	Lawyer
Mrs.Anitha Natarajan	Lay Person

Approval / Clearance is hereby given for this Thesis / Project.
 Yours Sincerely,


Dr.Sushmita Ann.S.J.,
 MBBS., MD(Pharmacology)
 Reg.No: 78375


 MEMBER SECRETARY
 ETHICS COMMITTEE
 Dr. JEYASEKHARAN MEDICAL TRUST

References

1. Tribble MA, Gregg CR, Margolis DM, Amir Khan R, Smith JW. Fatal ergotism induced by an HIV protease inhibitor. *Headache: The Journal of Head & Face Pain*. 2002 Jul 1;42(7).
2. Kim MD, Lee G, Shin SW. Ergotamine-induced upper extremity ischemia: a case report. *Korean J Radiol* 2005;6(2):130–2.
3. O'Dell CW, Davis GB, Johnson AD, Safdi MA, Brant-Zawadzki M, Bookstein JJ. Sodium nitroprusside in the treatment of ergotism. *Radiology* 1977;124(1):73–4.
4. Dierckx RA, Peters O, Ebinger G, Six R, Corne L. Intraarterial sodium nitroprusside infusion in the treatment of severe ergotism. *Clin Neuropharmacol* 1986;9(6):542–8.
5. Bongard JD, et al. Limb-threatening ischemia due to ergotamine: case report with review of treatment including sodium nitroprusside. *Headache* 2000;40(5):381–4.
6. Enge I, Sivertssen E. Ergotism due to therapeutic doses of ergotamine tartrate. *American Heart Journal*. 1965 Nov 1;70(5):665-70.
7. Urga K, Debella A, Agata N, Bayu A, Zewdie W. Laboratory studies on the outbreak of gangrenous ergotism associated with consumption of contaminated barley in Arsi, Ethiopia. *Ethiopian Journal of Health Development*. 2002;16(3):317-23.
8. Lee MR. The history of ergot of rye (*Claviceps purpurea*) I: from antiquity to 1900. *Journal of the Royal College of Physicians of Edinburgh*. 2009 Jun;39(2):179-84.
9. Schiff Jr PL. Ergot and its alkaloids. *American journal of pharmaceutical education*. 2006 Oct 15;70(5):98.
10. Baldwin ZK, Ceraldi CC. Ergotism associated with HIV antiviral protease inhibitor therapy. *Journal of vascular surgery*. 2003 Mar 1;37(3):676-8.
11. Garcia GD, Goff Jr JM, Hadro NC, O'Donnell SD, Greatorex PS. Chronic ergot toxicity: A rare cause of lower extremity ischemia. *Journal of vascular surgery*. 2000 Jun 1;31(6):1245-7.
12. MERHOFF CC, Porter JM. Ergot intoxication: historical review and description of unusual clinical manifestations. *Annals of surgery*. 1974 Nov 1;180(5):773-9.
13. Zavaleta EG, Fernandez BB, Grove MK, Kaye MD. St. Anthony's Fire (Ergotamine Induced Leg Ischemia) A Case Report and Review of the Literature. *Angiology*. 2001 May;52(5):349-56.
14. Schulz V. Treatment of ergotism. *Fortschritte der Medizin*. 1984 Feb 1;102(8):189-91.
15. Musikatavorn K, Suteparuk S. Ergotism unresponsive to multiple therapeutic modalities, including sodium nitroprusside, resulting in limb loss. *Clinical toxicology*. 2008 Jan 1; 46(2):157-8.